Flexion Therapeutics, Inc.

Flexion Therapeutics, Inc.

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis.

Flexion acquired GeneQuine’s pre-clinical human development program GQ-203 (now designated FX201) in December 2017 and is now advancing the program towards clinical development.

Back